Studying memory and thinking problems in adults with well-controlled HIV
Studies thinking problems in adults with HIV controlled by medicine, and healthy adults.
Key facts
- Who runs it
- National Institute of Neurological Disorders and Stroke (NINDS)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Thinking and Memory Problems in People With HIV
- Status
- Recruiting
- People taking part
- 1,150 people, planned
- Started
- 8 Jul 2013
- Expected to end
- 22 Feb 2037
- Type of study
- Observational, 3 groups
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with HIV whose virus has been well controlled by medicine for over a year, and for adults without HIV as comparison volunteers. It studies thinking and memory problems.
- Age
- 18 years and older (up to 110 years).
- Sex
- All sexes can join.
- Disease stage
- People with HIV-1 infection and a plasma HIV-RNA below 50 copies/mm3 or not detectable for more than one year. Short, temporary rises above 50 copies/mm3 are allowed if levels were below 50 before and after.
- Earlier treatment
- People with HIV must have taken antiretroviral therapy (ART) without a break for at least one year.
- Biomarker or test result
- People with HIV: documented HIV-1 infection by a rapid test or Western Blot. Comparison volunteers: HIV-antibody negative (taking PrEP is allowed).
Main reasons for not taking part
- Current or untreated brain or spinal cord infections
- Other conditions that cause memory loss or dementia, such as Alzheimer's or Parkinson's disease
- Severe, unstable mental illness or active substance abuse
- Cannot have an MRI scan, for example because of a pacemaker or metal implants
- Pregnancy
The registry criteria, word for word
Show all 18 criteriaShow less
Who cannot take part
- Concurrent severe, unstable psychiatric illness that, in the opinion of the investigators, may interfere with study participation and/or data interpretation. Participants on psychotropic anxiolytic, attention deficit-hyperactivity disorder (ADHD), and other psychiatric medications may be included if clinically stable for 6 months
- Concurrent substance abuse that, in the opinion of the investigators may interfere with study participation and/or data interpretation. Active substance abuse includes illegal drug use and/or excessive narcotic or alcohol use as determined by the investigator. Urine drug screen will be performed on all participants. Use of nicotine containing products will not be an exclusion criterion
- Contraindication to MRI scanning, including pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and cochlear implants), implanted delivery pump, or shrapnel fragments. Participants requiring a low dose oral benzodiazepine for mild to moderate claustrophobia will be allowed to participate. Pregnancy testing will be performed in enrolled participants of childbearing potential 48 hours prior to any MRI
- Prior or planned/anticipated exposure to radiation due to clinical care or participation in other research protocols, which would exceed the recommended acceptable annual limit of radiation exposure once accounting for the requirements of the current study
- Illness or other condition that, in the opinion of the PI, may interfere with study participation at the time of enrollment, including, but not limited to those listed below:; CNS infections: this includes but is not limited to Varicella zoster virus (VZV) encephalitis, CNS lymphoma and toxoplasmosis. Participants who have recovered from effectively treated CNS infections may be considered once they resume baseline daily activities; Non-CNS opportunistic infections: Participants who recovered from or are completing treatment for non-CNS opportunistic infections (Ois) (e.g., Pneumocystis pneumonia, Candida esophagitis, or pulmonary TB) can be enrolled if they have returned to self-reported baseline activity and functional level
- Conditions other than HAND associated with cognitive impairment or dementia such as Alzheimer's, Parkinson's disease, head injury with loss of consciousness >30 minutes, untreated sleep apnea with day-time sleepiness, or seizure disorders. Participants with a history of seizure disorder with no seizure activity that are on a stable, non-sedating anti-seizure regimen for >6 months may be enrolled
- Medications: narcotics, psychiatric, and anti-seizure medications will not be allowed except under certain conditions as noted above. Corticosteroids may be permitted for participants on stable short-term therapy without CNS disease (i.e. resolving Pneumocystis pneumonia). Participants must be willing not to take the following medications within 48 hours of neuropsychological testing: sedating antihistamines such as diphenhydramine, zolpidem and other drugs identified by the study team that are associated with altered alertness or impaired memory
- Pregnant persons are excluded due to exposure to high magnetic fields There is also exposure to radiation from the lumbar puncture if done under fluoroscopy. Participants of childbearing potental must have a negative serum or urine pregnancy 48 hours prior to any radiation exposure
Other criteria
- INCLUSION CRITERIA:; All Participants (HIV-infected and HIV-negative Controls):; While different individual HIV neurocognitive studies have specific selection criteria, especially related to HIV viral load and antiretroviral therapy, inclusion criteria for this overarching protocol will be flexible in order to identify the broadest base of potential enrollees possible
- 18 years of age and older
- Ability to sign informed consent by the participant
- At least seventh grade educational level and ability to speak, read, and understand English. Education level will be assessed by participant self-report. Because many of the neuropsychological subtests were validated using United States norms, participants must be native English speakers or if foreign-born, demonstrate ability to understand the English language at the time of protocol consent and neuropsychological testing
- Consent to store blood and tissue
- Willing to participate in this study for up to 20 years; HIV-infected Only:
- HIV-1 infection, as documented by OraQuick rapid test using venipuncture whole blood, or fingerstick whole blood; or with HIV-1/HIV-2 Multispot rapid test and Western Blot as determined by NIH Clinical Pathology Laboratory or Leidos Biomedical Research. Monitoring Laboratory
- Outside primary medical doctor who provides care
- Plasma HIV-RNA <50 copies/mm3 or BLD for greater than one year. Participants who experience transitory episodes of an HIV viral load > 50 copies/mm3 preceded and followed by plasma viremia < 50 copies/mm3 may be included
- At least one year of continuous ART; HIV-negative Controls Only:; 1.HIV-antibody negative but can be taking pre-exposure prophylaxis (PrEP)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 110 years old?
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Amanda M WieboldTaking people
About the trial
What the trial wants to find out
Background:
Read full original descriptionShow less
- People with human immunodeficiency virus (HIV) can sometimes develop thinking and memory problems. These problems can vary widely, from few symptoms to severe problems with memory and concentration. It initially was thought that good HIV treatment could prevent almost all HIV-related memory problems. However, even people with low HIV viral loads can have these problems. It may be caused by HIV affecting the brain and spinal fluid. It is not yet clear why HIV causes these problems and why they may be worse in some people than others. Researchers want to study people with HIV and healthy volunteers to see how HIV may affect people with only small amounts of the virus in their blood.
Objectives:
- To study thinking and memory problems in individuals with HIV that is otherwise controlled with medications.
Eligibility:
* Individuals between 18 of age or older whose HIV has been controlled with medications for at least 1 year. * Healthy volunteers between 18 of age or older.
Design:
* Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. A neurological test will also be given. Participants will have a baseline imaging study of the brain. * Within 12 weeks of the first visit, participants will have a second visit. Additional blood samples will be drawn. Another brain imaging study will be performed. * Within 8 weeks of the second visit, participants will have a third visit to collect more blood samples. They will also provide spinal fluid samples, either as a single visit or a longer procedure. * After this visit, participants will return every 12 months for up to 10 years. Blood samples will be collected as needed at these visits. Thinking and memory tests and imaging studies may also be given as needed. Spinal fluid may be collected at one visit a year.
The 3 groups in the trial
- DOD
Participants that are from IDCRP
- HIV negative controls
Participants that do not have HIV infection
- HIV positive
Participants that have HIV infection
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Evaluation of HIV-associated Neurocognitive Disorders (HAND) in Virologically Controlled Patients
- Plain-language title
- Studying memory and thinking problems in adults with well-controlled HIVGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT01875588, who can take part
- Record updated
- 13 October 2026